Deals this week: HTG Molecular Diagnostics, Glytec, Cellnovo


Medical device company HTG Molecular Diagnostics has signed a research agreement with Centre Leon Berard, a non-profit organisation involved in molecular profiling studies, to advance precision medicine.

The research project will utilise the HTG EdgeSeq oncology biomarker panel to retrospectively characterise immunologic profiles from advanced malignant tumour samples collected in the ProfiLER study.

Collaboration enables immunogenic profiling of tumours and allows for the identification of biomarkers with a potential predictive value and for detecting whether certain genetic disorders are linked to immunity status alteration.

Israel-based compact MRI systems developer Aspect Imaging has raised $30m with the help of the company’s existing investors.

Funds will be used to continue the development of its Embrace Neonatal MRI system and its new Stroke-dedicated MRI System.

Digital health care company Livongo Health and glycemic management solutions company Glytec have partnered to develop a new eGlycemic Management System (eGMS) for Livongo members.

The two companies will work to deliver an expanded diabetes management solution that includes insulin titration.

The expanded solution will provide improved health for diabetic patients, by integrating medication data, monitoring and optimised medication adherence.

Diabetes-related medical technology company Cellnovo has signed a worldwide commercial licensing agreement with TypeZero Technologies.

"Collaboration enables immunogenic profiling of tumours and allows for the identification of biomarkers with a potential predictive value and for detecting whether certain genetic disorders are linked to immunity status alteration."

The agreement includes the integration of TypeZero Technologies' artificial pancreas (AP) technology, known as inControl AP, into Cellnovo's Bluetooth-enabled mobile diabetes management system.

Cellnovo will be responsible for the commercialisation of the product, which is expected to be launched in 2018.

Medical technology company NeuroTronik has raised $23.1m in a series B preferred stock financing round led by Boston Scientific Group.

Financing is in line with the company’s project-plan milestones and will be used to advance the development of its NeuroTronik CANS Therapy system, an investigational therapy to improve the treatment of acute heart failure (AHF). It will also help the company to receive CE Mark approval for the therapy system.